Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 12—December 2011


Candidate Cell Substrates, Vaccine Production, and Transmissible Spongiform Encephalopathies

Pedro PiccardoComments to Author , Larisa Cervenakova, Irina Vasilyeva, Oksana Yakovleva, Igor Bacik, Juraj Cervenak, Carroll McKenzie, Lubica Kurillova, Luisa Gregori, Kitty Pomeroy, and David M. Asher
Author affiliations: University of Edinburgh, Easter Bush, UK, (P. Piccardo); Food and Drug Administration, Kensington, Maryland, USA (P. Piccardo, I. Bacik, J. Cervenak, L. Kurillova, L. Gregori, K. Pomeroy, D.M. Asher); Holland Laboratory American Red Cross, Rockville, Maryland, USA (L. Cervenakova, I. Vasilyeva, O. Yakovleva, C. McKenzie)

Main Article

Table 2

Cell lines exposed to BSE or vCJD or normal bovine or human brain suspension and bioassayed in TgBo mice*

CHO 21 9 720 17 9 730
Vero 20 10 730 ND ND ND
WI-38 23 10 730 ND ND ND
R9ab 18 9 630 ND ND ND
MDCK 19 10 730 20 10 730
HEK-293 20 20 730 ND ND ND
Mo3F4-3T3 17 10 750 ND ND ND

*BSE, bovine spongiform encephalopathy; vCJD, variant Creutzfeldt-Jakob disease; NB, normal brain; dpi, days postinculation at cull; ND, not done; CHO, Chinese hamster ovary; Vero, African green monkey kidney; WI-38, human lung diploid fibroblasts; R9ab, rabbit fibroblasts; MDCK, dog kidney; HEK-293, human embryonic kidney; Mo3F4-3T3, mouse fibroblasts.

Main Article